EKCS yields 500000.00% · ABBV yields 3.09%● Live data
📍 EKCS pulled ahead of the other in Year 1
Combined, EKCS + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of EKCS + ABBV for your $10,000?
Electronic Control Security Inc. designs, develops, manufactures, and markets technology-based integrated security solutions in the United States and the Middle East. The company offers entry control system, which regulates the passage of authorized vehicles and personnel into restricted areas; fiber optic intelligence and detection system; infrared perimeter intrusion detection systems provides dependable security barriers of pulsed infrared beams to create multiple detection zones; flight line security for aircraft parking areas, igloos and flight lines at air bases; rapid deployable intrusion detection systems; day/night and thermal imaging cameras; intelligent video motion detection; ARTSYS 360 - advanced radar technologies radar systems designed for detection and tracking of vehicles, humans, and drones; water infrastructure sensing equipment; and interoperable device management systems. It also provides site survey and risk assessment; design and engineering; systems manufacturing and integration; factory acceptance testing; installation supervision; and project commissioning services. The company was founded in 1976 and is headquartered in Clifton, New Jersey.
Full EKCS Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.